Orchid Pharma Limited (ORCHPHARMA.NS)
INR 719.7
(1.92%)
INR 719.7
(1.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.84 Billion INR | -28.36% |
| 2022 | 5.36 Billion INR | 15.84% |
| 2021 | 4.63 Billion INR | -20.73% |
| 2020 | 5.84 Billion INR | -16.2% |
| 2019 | 6.97 Billion INR | -81.56% |
| 2018 | 37.81 Billion INR | -3.47% |
| 2017 | 39.17 Billion INR | 4.58% |
| 2016 | 37.45 Billion INR | -1.77% |
| 2015 | 38.13 Billion INR | 2.17% |
| 2014 | 37.32 Billion INR | -12.61% |
| 2013 | 42.7 Billion INR | 0.0% |
| 2011 | 28.02 Billion INR | -6.55% |
| 2010 | 29.99 Billion INR | 5.76% |
| 2009 | 28.35 Billion INR | -21.23% |
| 2008 | 36 Billion INR | 27.7% |
| 2007 | 28.19 Billion INR | 17.18% |
| 2006 | 24.05 Billion INR | 72.72% |
| 2005 | 13.92 Billion INR | 3.05% |
| 2004 | 13.51 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -11.69 Billion INR | -404.23% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 3.84 Billion INR | -28.36% |
| 2023 Q2 | 3.84 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 3.84 Billion INR | 0.0% |
| 2022 Q2 | 5.43 Billion INR | 0.0% |
| 2022 Q4 | 5.36 Billion INR | 0.0% |
| 2022 FY | 5.36 Billion INR | 15.84% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 4.63 Billion INR | -20.73% |
| 2021 Q4 | 4.63 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 4.41 Billion INR | 0.0% |
| 2020 Q2 | 6.29 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 5.84 Billion INR | 0.0% |
| 2020 FY | 5.84 Billion INR | -16.2% |
| 2020 Q1 | - INR | -100.0% |
| 2019 FY | 6.97 Billion INR | -81.56% |
| 2019 Q4 | 6.97 Billion INR | 0.0% |
| 2019 Q1 | - INR | 0.0% |
| 2018 FY | 37.81 Billion INR | -3.47% |
| 2018 Q2 | 38.21 Billion INR | 0.0% |
| 2017 FY | 39.17 Billion INR | 4.58% |
| 2016 FY | 37.45 Billion INR | -1.77% |
| 2015 FY | 38.13 Billion INR | 2.17% |
| 2014 FY | 37.32 Billion INR | -12.61% |
| 2013 FY | 42.7 Billion INR | 0.0% |
| 2013 Q2 | 42.19 Billion INR | 0.0% |
| 2011 FY | 28.02 Billion INR | -6.55% |
| 2011 Q4 | 28.02 Billion INR | 0.0% |
| 2010 FY | 29.99 Billion INR | 5.76% |
| 2009 FY | 28.35 Billion INR | -21.23% |
| 2008 FY | 36 Billion INR | 27.7% |
| 2007 FY | 28.19 Billion INR | 17.18% |
| 2006 FY | 24.05 Billion INR | 72.72% |
| 2005 FY | 13.92 Billion INR | 3.05% |
| 2004 FY | 13.51 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 76.379% |
| Hester Biosciences Limited | 3.59 Billion INR | -6.937% |
| Aarti Drugs Limited | 11.5 Billion INR | 66.585% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 53.409% |
| Albert David Limited | 1.15 Billion INR | -234.237% |
| Alembic Limited | 1.43 Billion INR | -168.422% |
| Alkem Laboratories Limited | 48.6 Billion INR | 92.091% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -489.33% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 21.028% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1231.057% |
| Brooks Laboratories Limited | 248.6 Million INR | -1446.284% |
| Eris Lifesciences Limited | 38.26 Billion INR | 89.955% |
| FDC Limited | 3.7 Billion INR | -3.636% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 25.803% |
| Gufic Biosciences Limited | 5.59 Billion INR | 31.353% |
| Hikal Limited | 12.99 Billion INR | 70.419% |
| Ind-Swift Limited | 13.45 Billion INR | 71.426% |
| Innova Captab Limited | 4.89 Billion INR | 21.547% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 39.262% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1195.349% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 93.726% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -257.74% |
| Lupin Limited | 96.23 Billion INR | 96.006% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -94.508% |
| Medico Remedies Limited | 438.24 Million INR | -777.155% |
| Morepen Laboratories Limited | 4.45 Billion INR | 13.806% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 65.733% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -50.089% |
| RPG Life Sciences Limited | 1.38 Billion INR | -178.516% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -497.015% |
| Sigachi Industries Limited | 2.53 Billion INR | -51.864% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 72.721% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -88.97% |
| Themis Medicare Limited | 1.88 Billion INR | -103.659% |
| Unichem Laboratories Limited | 8.06 Billion INR | 52.361% |
| Vaishali Pharma Limited | 371.16 Million INR | -935.685% |
| Wanbury Limited | 3.15 Billion INR | -21.821% |
| Windlas Biotech Limited | 1.76 Billion INR | -118.079% |
| ZIM Laboratories Limited | 2.08 Billion INR | -84.744% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -67.903% |
| Ipca Laboratories Limited | 33.74 Billion INR | 88.608% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 97.906% |
| Venus Remedies Limited | 1.39 Billion INR | -175.996% |
| Sakar Healthcare Limited | 1.26 Billion INR | -204.293% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 97.474% |
| Divi's Laboratories Limited | 18.99 Billion INR | 79.757% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -4.998% |
| Mankind Pharma Limited | 23.87 Billion INR | 83.899% |
| Sequent Scientific Limited | 8.27 Billion INR | 53.542% |
| Laurus Labs Limited | 42.71 Billion INR | 91.001% |
| Neuland Laboratories Limited | 5.49 Billion INR | 30.089% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 64.101% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 94.096% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 94.646% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -390.426% |
| Wockhardt Limited | 39.87 Billion INR | 90.358% |
| Bal Pharma Limited | 2.51 Billion INR | -53.073% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 96.406% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -82.283% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -2305.691% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -9.655% |
| Shilpa Medicare Limited | 12.93 Billion INR | 70.276% |
| Valiant Laboratories Limited | 1.05 Billion INR | -263.245% |
| Ajanta Pharma Limited | 10.71 Billion INR | 64.109% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -123.209% |
| Granules India Limited | 22.95 Billion INR | 83.253% |
| Medicamen Biotech Limited | 940.36 Million INR | -308.785% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -229.904% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.314% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 95.315% |
| NATCO Pharma Limited | 10.53 Billion INR | 63.501% |
| Suven Life Sciences Limited | 148.62 Million INR | -2486.497% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -29.26% |
| Strides Pharma Science Limited | 37.68 Billion INR | 89.798% |
| Indoco Remedies Limited | 10.34 Billion INR | 62.831% |
| Alpa Laboratories Limited | 307.12 Million INR | -1151.645% |
| Lasa Supergenerics Limited | 541.92 Million INR | -609.338% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 1.254% |